High morbidity and mortality found for high-risk, non–muscle-invasive bladder cancer
A partir de données portant sur 4 545 cas, cette étude américaine fait le point sur les morbidités et la mortalité des patients atteints d'une tumeur superficielle de la vessie à haut risque de récidive
Nearly 75% of patients with high-risk, non–muscle-invasive bladder cancer recur, progress, or die within 10 years of their diagnosis, according to a recent study published in Cancer (published online ahead of print June 4, 2013. doi: 10.1002/cncr.28147). In this article, Karim Chamie, MD, MSHS, assistant professor in the department of urology at the University of California at Los Angeles and colleagues note that the bladder cancer-related mortality rate has dropped only 5% in the last 15 years, a slower decline than for most other solid tumors. They hypothesized that quality of care may be at least part of the problem and noted that suboptimal care (eg, not following guidelines) has been documented in patients with advanced and early bladder cancer. A previous claims-based study of 4545 cases of high-grade, non–muscle-invasive bladder cancer found that only one patient received all the follow-up surveillance and treatments recommended in national guidelines, including those from the American Urological Association and the National Comprehensive Cancer Network (Cancer. 2011;117:5392-5401). Using data from the same study, researchers found that patients who received at least one-half of the recommendations had a statistically significant survival advantage (Cancer. 2012;118:1412-1421). The objective of the current study was to better elucidate the natural history of high-grade, non–muscle-invasive bladder cancer in terms of recurrence, progression, and cancer-related mortality.